MAIA Biotechnology Inc. Stock Price, News & Analysis

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced plans for additional insider investments by its CEO, Vlad Vitoc, and Board Member, Stan Smith, Ph.D., under Rule 10b5-1 trading plans. These plans allow purchases of common stock under regulated conditions. Vitoc expressed confidence that MAIA's valuation does not reflect its growth potential, highlighting innovative assets in oncology. Smith reiterated his commitment, noting the company's revolutionary approach to cancer treatment. MAIA focuses on developing first-in-class oncology drugs, particularly a telomere targeting agent for NSCLC.

MAIA Biotechnology announced promising results for its lead drug candidate, THIO, from a pre-clinical study on hepatocellular carcinoma (HCC) presented at the SITC 37th Annual Meeting. The study showed that THIO enhances the efficacy of immune checkpoint inhibitors by directly killing cancer cells and stimulating an anti-tumor immune response. Notably, THIO, which received Orphan Drug Designation from the FDA, exhibited complete responses in several HCC models with no dose-limiting toxicities. MAIA emphasizes THIO's potential to address the growing need for effective HCC treatments.

MAIA Biotechnology, Inc. reported financial results for Q3 2022, highlighting a net loss of approximately $3.9 million, an improvement from $5.2 million in Q3 2021. The company’s cash position increased to about $14.1 million, sufficient for 12 months of operations. Key developments include an oral presentation on the THIO platform and ongoing THIO-101 trial disclosures. MAIA was added to the Longevity Stock Index, emphasizing its focus on cancer immunotherapies targeting telomeres.

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced its participation in the ThinkEquity Conference on October 26 at 3:00 pm ET. The management team will present and host investor meetings during the event. A webcast of the presentation will be accessible via the Company's website, with a replay available for 30 days post-event. MAIA focuses on developing first-in-class oncology drugs, particularly THIO for NSCLC.

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced it will present study results of the anticancer agent 6-thio-dG (THIO) for hepatocellular carcinoma (HCC) at the EORTC-NCI-AACR Symposium, occurring in Barcelona, Spain from Oct. 26-28, 2022. The data indicates THIO's high anticancer activity and improved tumor response when used sequentially with cemiplimab in HCC models. The U.S. FDA granted THIO Orphan Drug Designation for HCC earlier in 2022, a disease projected to exceed 1 million global cases by 2025.

Presentation is scheduled for Oct. 26 at 12:00pm CEST.

MAIA Biotechnology, Inc. (NYSE American: MAIA) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14. The management team is set to present on September 12 at 7:00 am ET and will hold investor meetings until September 14. A webcast of the presentation will be available on the Company's website, with a replay accessible for 30 days post-event. MAIA focuses on developing first-in-class oncology drugs aimed at improving cancer treatment outcomes.

MAIA Biotechnology, Inc. (NYSE American: MAIA) announced the upcoming presentation of its ongoing THIO-101 trial design at the ESMO Congress 2022 in Paris from September 9-13. The trial evaluates THIO, a telomere-targeting agent, in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC). The first patient was enrolled in July 2022 in Australia. The presentation is scheduled for September 12, under the title: 'A Phase 2, Multicenter, Open-Label, Dose-Finding Study Evaluating THIO Sequenced with Cemiplimab in Patients with Advanced NSCLC'.

MAIA Biotechnology, Inc. has been selected to present its innovative THIO platform at the XIV International Round Table on Nucleosides in Stockholm, Sweden, from August 28 to 31, 2022. This platform showcases the modified nucleoside 6-thio-2’-deoxyguanosine (6-thio-dG) as a promising anticancer agent. The presentation will highlight how THIO may enhance immune responses and overcome therapy resistance. MAIA aims to develop THIO for non-small cell lung cancer patients resistant to existing checkpoint inhibitors.

MAIA Biotechnology, Inc. (NYSE American: MAIA) reported its second-quarter 2022 financial results, highlighting significant advancements in its clinical development of THIO, an immunotherapy for cancer. The company has initiated a Phase 2 trial for Non-Small Cell Lung Cancer (NSCLC) and received orphan drug designations from the FDA for two additional indications: Small Cell Lung Cancer (SCLC) and Hepatocellular Carcinoma (HCC). MAIA completed its IPO on August 1, raising $11.5 million, and reported a net loss of approximately $3.3 million for the quarter.